
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics is expected to see continued growth in 2026 due to the release of their Q2 financial and operational results, including a Preliminary Economic Assessment with a positive after-tax NPV5% and IRR. Additionally, the recent repurchase of shares and quarter dividend payment show the company's commitment to returning capital to shareholders, which further strengthens its financial position. With its strong product offerings and expansion into new markets, 10x Genomics is well-positioned for continued success in the years to come.
Bears say
10x Genomics is facing significant risks to achieving its projected target due to increasing competition in the life science technology industry, the potential for its technology to become obsolete, and potential disruptions in its supply chain. These risks, along with the company's dependence on key customers and potential regulatory challenges, warrant a negative outlook on the stock. Relevant financial data that may support this outlook includes the fact that the company has a P/E ratio of 338.72, indicating a high valuation that may not be justified by its financial performance.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares